Monthly extended-release Buprenorphine given via a mobile clinic for opioid use disorder
Official title: Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study
Run by Yale University · NCT07176351 · Data updated 2026-11-12
This project tests whether monthly extended-release subcutaneous buprenorphine can be feasibly and acceptably delivered from a mobile pharmacy clinic to people with opioid use disorder.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Status | Recruiting |
| Started | September 23, 2026 |
| Main results expected | February 2027 |
| Study ends | February 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07176351 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with current or past moderate-to-severe OUD who speak English or Spanish and remain in the area for the 6-month study period.
✕Probably not a fit
Individuals not planning to stay in the area or those with medical or psychiatric conditions making participation unsafe or unlikely to complete follow-up may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective cohort study evaluating the feasibility and acceptability of providing BRIXADI (XR-B) subcutaneous buprenorphine on a mobile pharmacy clinic for individuals with opioid use disorder. Participants choose between weekly or monthly XR-B formulations with dosing based on clinical need, and receive free medication for 6 months. Data on medical visits and records will be collected to assess practicality, adherence, and patient experience. Shared decision-making with a clinician guides formulation choice and administration. The study seeks to determine if mobile delivery can support ongoing treatment in the community setting.
Why it matters
Potential benefit: If successful, this approach could improve access to long-acting buprenorphine for people with OUD who face barriers to traditional clinic-based care.
How similar studies have gone: Prior work with long-acting buprenorphine shows promise; this study extends that approach to a mobile clinic setting to test feasibility in real-world community care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to provide written informed consent in English or Spanish * Current or history of DSM-5 moderate-to-severe OUD per Rapid Opioid Use Disorder Assessment (ROUDA) * Not planning to move out of state or to new location during study enrollment. Exclusion Criteria: * Medical or psychiatric disorders making participation unsafe or regular follow-up unlikely, (such as suicidal ideation or pre-existing moderate to severe hepatic impairment) * Persons who are pregnancy * People who show violent or threatening behavior toward staff and/or others * Allergy, hypersensitivity, or medical contraindication to medication (the BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in persons with latex-sensitivity)
Where it's running
-
Yale School of Medicine
New Haven, Connecticut, United States Recruiting
Study contacts
- Principal investigator: Sandra Springer, MD — Yale University
- Study coordinator: Sandra Springer, MD
- Email: sandra.springer@yale.edu
- Phone: 203-687-6680
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand
This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.
-
STORC: Training a support person plus patient navigation after birth
We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.
-
Personalized Addiction Treatment Enhancement for Opioid Use Disorder
A digital platform run by peer recovery supporters will be tested to help adults with opioid use disorder who are on buprenorphine or methadone stay in treatment and improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.